INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Public company

ESLAEstrella Immunopharma, Inc.

CIK 0001844417

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 0
Max Insider Score20
Connections3with evidence

ESLA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
PC
Pussinen CynthiaDirector, Chief Executive Officer
ESLAEstrella Immunopharma, Inc.
Grant or award
A—
1.00M sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Pussinen CynthiaDirector, Chief Executive Officer · Nov 4, 2026
  • ← Insider ofevidence
    Liu ChengDirector, CEO · Aug 26, 2026
20
LC
Liu ChengDirector, CEO
ESLAEstrella Immunopharma, Inc.
Option exercise
M
$82K
100.0K sh
Aug 25, 2026
Aug 26, 2026
traded Aug 25, 2026
+1d
SEC FORM 4

Evidence

13
LC
Liu ChengDirector, CEO
ESLAEstrella Immunopharma, Inc.
Option exercise
M—
100.0K sh
Aug 25, 2026Aug 26, 2026
traded Aug 25, 2026
+1dSEC FORM 4

Evidence

Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago